GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Innophos Holdings Inc (NAS:IPHS) » Definitions » EBIT
中文

Innophos Holdings (Innophos Holdings) EBIT

: $56.2 Mil (TTM As of Sep. 2019)
View and export this data going back to 2006. Start your Free Trial

Innophos Holdings's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2019 was $13.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2019 was $56.2 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Innophos Holdings's annualized ROC % for the quarter that ended in Sep. 2019 was 4.97%. Innophos Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2019 was 11.18%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Innophos Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2019 was 8.92%.


Innophos Holdings EBIT Historical Data

The historical data trend for Innophos Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innophos Holdings Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 101.22 47.09 77.36 63.34 56.40

Innophos Holdings Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.92 11.74 15.93 15.31 13.24

Competitive Comparison

For the Specialty Chemicals subindustry, Innophos Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innophos Holdings EV-to-EBIT Distribution

For the Chemicals industry and Basic Materials sector, Innophos Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Innophos Holdings's EV-to-EBIT falls into.



Innophos Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $56.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innophos Holdings  (NAS:IPHS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Innophos Holdings's annualized ROC % for the quarter that ended in Sep. 2019 is calculated as:

ROC % (Q: Sep. 2019 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2019 ) + Invested Capital (Q: Sep. 2019 ))/ count )
=54.728 * ( 1 - 30.81% )/( (755.119 + 767.286)/ 2 )
=37.8663032/761.2025
=4.97 %

where

Invested Capital(Q: Sep. 2019 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=875.844 - 77.827 - ( 30.731 - max(0, 116.505 - 342.376+30.731))
=767.286

Note: The Operating Income data used here is four times the quarterly (Sep. 2019) data.

2. Joel Greenblatt's definition of Return on Capital:

Innophos Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2019 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2019 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2019  Q: Sep. 2019
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=52.948/( ( (286.953 + max(181.057, 0)) + (293.4 + max(186.075, 0)) )/ 2 )
=52.948/( ( 468.01 + 479.475 )/ 2 )
=52.948/473.7425
=11.18 %

where Working Capital is:

Working Capital(Q: Jun. 2019 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(98.957 + 172.455 + 22.607) - (82.996 + 9.623 + 20.343)
=181.057

Working Capital(Q: Sep. 2019 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(106.219 + 170.29 + 19.241) - (77.827 + 9.623 + 22.225)
=186.075

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2019) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Innophos Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2019 )
=56.212/629.910
=8.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innophos Holdings EBIT Related Terms

Thank you for viewing the detailed overview of Innophos Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Innophos Holdings (Innophos Holdings) Business Description

Traded in Other Exchanges
N/A
Address
259 Prospect Plains Road, Cranbury, NJ, USA, 08512
Innophos Holdings Inc is a holding company that manufactures and sells through its subsidiaries a variety of ingredients used in the production of food, beverages, dietary supplements, pharmaceuticals, and oral care products. Innophos ingredients are made primarily from specialty phosphates. The company organizes itself into three segments namely Food, Health and Nutrition; Industrial Specialties and Other. The Food, Health and Nutrition segment contribute the maximum revenue. The company operates in U.S., Canada, Mexico and other countries.
Executives
John M Steitz director ALBEMARLE CORP, 451 FLORIDA ST, BATON ROUGE LA 70801
Kim Ann Mink director, officer: Chairman, CEO, President 259 PROSPECT PLAINS RD., BLDG A, CRANBURY NJ 08512
Gary A Cappeline director 50 E RIVERCENTER BLVD, COVINGTON KY 41012
Karen R Osar director C/O WESTVACO CORP, ONE HIGH RIDGE PARK, STAMFORD CT 06905
Mark Santangelo officer: Sr. VP, Mfg, Eng & EH&S 15710 JOHN F. KENNEDY BLVD., SUITE 300 HOUSTON TX 77032
Peter T Thomas director 1000 LAKESIDE AVENUE, CLEVELAND OH 44114
Hermanus Kieftenbeld officer: Senior VP and CFO 259 PROSPECT PLAINS RD., BLDG A, CRANBURY NJ 08512
James P. Zallie director 5 WESTBROOK CORPORATE CENTER, WESTCHESTER IL 60154
Randy Gress director, officer: CEO 259 PROSPECT PLAINS ROAD, P O BOX 8000, CRANBURY NJ 08512-8000
Stephen M Zide director BAIN CAPITAL PARTNERS, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Richard Heyse officer: VP-Chief Financial Officer 259 PROSPECT PLAINS ROAD, BUILDING G, P O BOX 8000, CRANBURY NJ 08512-8000
Bain Capital Investors Llc 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Partners Vii Lp 10 percent owner JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Fund Vii Llc 10 percent owner JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Fund Vii Lp 10 percent owner JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116